Astellas Pharma Inc (4503):企業の財務・戦略的SWOT分析

◆英語タイトル:Astellas Pharma Inc (4503) - Financial and Strategic SWOT Analysis Review
◆商品コード:DATA904C8764
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:74
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:日本
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD125 ⇒換算¥18,500見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD375 ⇒換算¥55,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Astellas Pharma Inc (4503) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Astellas Pharma Inc (Astellas) is a research based pharmaceutical company that discovers, develops, manufactures, and commercializes a wide range of pharmaceuticals. The company’s product portfolio comprises both marketed products for the treatment of a wide range of urological diseases, infectious diseases, cancer, diseases and disorders of central nervous system (CNS), and metabolic diseases, immunodeficiency diseases, and transplantation. The company is investigating enfortumab vedotin in Phase 2 and Phase 3 clinical trials for the treatment of urothelial cancer; zolbetuximab in Phase 3 clinical trials for the treatment of gastric cancer and gastroesophageal junction cancer; roxadustat in Phase 3 clinical studies for the treatment of patients with anemia associated with chronic kidney disease (CKD) in patients on dialysis and non-dialysis; fezolinetant in Phase 2a clinical trials for the treatment of menopause-related vasomotor symptoms (MR-VMS) such as hot flashes and night sweats; and gilteritinib for the treatment of for acute myeloid leukemia (AML). It operates in the Americas; Europe; and Asia and Oceania through its network of subsidiaries and affiliates. Astellas is headquartered in Tokyo, Japan.

Astellas Pharma Inc Key Recent Developments

Oct 23,2018 Astellas and BANDAI NAMCO entertainment to jointly develop Smartphone Exercise Support App
Oct 16,2018 Cytokinetics Unveils Expanded Development Pipeline and Provides Key Updates on Late-Stage Clinical Research Programs at R&D Day
Oct 09,2018 Astellas details progress and commitment to patients and the community in the company’s americas 2017 corporate social responsibility report card
Oct 09,2018 Astellas, Mitsubishi Tanabe Pharma, and Daiichi Sankyo announce second public recruitment offering of “Joinus”, a joint research program to discover new drugs using drug-repositioning compound library

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Section 1 – About the Company 6
Astellas Pharma Inc – Key Facts 6
Astellas Pharma Inc – Key Employees 7
Astellas Pharma Inc – Key Employee Biographies 11
Astellas Pharma Inc – Major Products and Services 12
Astellas Pharma Inc – History 15
Astellas Pharma Inc – Company Statement 27
Astellas Pharma Inc – Locations And Subsidiaries 28
Head Office 28
Other Locations & Subsidiaries 28
Joint Venture 33
Section 2 – Company Analysis 35
Company Overview 35
Astellas Pharma Inc – Business Description 36
Product Category: Betanis/Myrbetriq/BETMIGA 36
Performance 36
Product Category: Other 37
Performance 37
Product Category: Prograf 37
Performance 37
Product Category: Vesicare 37
Performance 37
Product Category: XTANDI 37
Performance 37
Geographical Segment: Americas 37
Performance 37
Geographical Segment: Asia and Oceania 37
Performance 37
Geographical Segment: EMEA 37
Performance 37
Geographical Segment: Japan 38
Performance 38
R&D Overview 38
Astellas Pharma Inc – Corporate Strategy 39
Astellas Pharma Inc – SWOT Analysis 40
SWOT Analysis – Overview 40
Astellas Pharma Inc – Strengths 40
Astellas Pharma Inc – Weaknesses 41
Astellas Pharma Inc – Opportunities 42
Astellas Pharma Inc – Threats 43
Astellas Pharma Inc – Key Competitors 44
Section 3 – Company Financial Ratios 45
Financial Ratios – Capital Market Ratios 45
Financial Ratios – Annual Ratios 46
Performance Chart 49
Financial Performance 49
Financial Ratios – Interim Ratios 50
Financial Ratios – Ratio Charts 51
Section 4 – Company’s Lifesciences Financial Deals and Alliances 52
Astellas Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 52
Astellas Pharma Inc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 53
Astellas Pharma Inc, Recent Deals Summary 54
Section 5 – Company’s Recent Developments 55
Oct 23, 2018: Astellas and BANDAI NAMCO entertainment to jointly develop Smartphone Exercise Support App 55
Oct 23, 2018: Astellas and BANDAI NAMCO entertainment to jointly develop Smartphone Exercise Support App 56
Oct 16, 2018: Cytokinetics Unveils Expanded Development Pipeline and Provides Key Updates on Late-Stage Clinical Research Programs at R&D Day 57
Oct 09, 2018: Astellas details progress and commitment to patients and the community in the company’s americas 2017 corporate social responsibility report card 60
Oct 09, 2018: Astellas, Mitsubishi Tanabe Pharma, and Daiichi Sankyo announce second public recruitment offering of “Joinus”, a joint research program to discover new drugs using drug-repositioning compound library 61
Oct 05, 2018: Cytokinetics and Astellas Provide Updates Regarding Collaborative Skeletal Muscle Program 62
Sep 18, 2018: Astellas Promotes Geoff Towle to Vice President of Oncology Marketing at Astellas US 66
Aug 14, 2018: Astellas Pharma acquires Quethera for $108.5m 67
Jun 08, 2018: Astellas names Nahrin Marino to Vice President, Head of Ethics & Compliance Americas 68
May 31, 2018: Astellas Oncology C3 Prize Returns for Third Year with Focus on Improving Cancer Care in Underserved Regions of the World 69
Section 6 – Appendix 70
Methodology 70
Ratio Definitions 70
About GlobalData 74
Contact Us 74
Disclaimer 74

List of Tables
Astellas Pharma Inc, Key Facts 6
Astellas Pharma Inc, Key Employees 7
Astellas Pharma Inc, Key Employees (cont..) 10
Astellas Pharma Inc, Key Employee Biographies 11
Astellas Pharma Inc, Major Products and Services 12
Astellas Pharma Inc, History 15
Astellas Pharma Inc, Other Locations 28
Astellas Pharma Inc, Subsidiaries 28
Astellas Pharma Inc, Joint Venture 33
Astellas Pharma Inc, Key Competitors 44
Astellas Pharma Inc, Ratios based on current share price 45
Astellas Pharma Inc, Annual Ratios 46
Astellas Pharma Inc, Annual Ratios (Cont...1) 47
Astellas Pharma Inc, Annual Ratios (Cont...2) 48
Astellas Pharma Inc, Interim Ratios 50
Astellas Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 52
Astellas Pharma Inc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 53
Astellas Pharma Inc, Recent Deals Summary 54
Currency Codes 70
Capital Market Ratios 70
Equity Ratios 71
Profitability Ratios 71
Cost Ratios 72
Liquidity Ratios 72
Leverage Ratios 73
Efficiency Ratios 73

List of Figures
Astellas Pharma Inc, Performance Chart (2014 - 2018) 49
Astellas Pharma Inc, Ratio Charts 51
Astellas Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 52
Astellas Pharma Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 53

★海外企業調査レポート[Astellas Pharma Inc (4503):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Intercontinental Exchange, Inc.:企業のM&A・事業提携・投資動向
    Intercontinental Exchange, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Intercontinental Exchange, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers …
  • Schaffer Corporation Limited (SFC):企業の財務・戦略的SWOT分析
    Schaffer Corporation Limited (SFC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …
  • HUP-Zagreb d.d.:企業の戦略・SWOT・財務情報
    HUP-Zagreb d.d. - Strategy, SWOT and Corporate Finance Report Summary HUP-Zagreb d.d. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Hoya Corp (7741):医療機器:M&Aディール及び事業提携情報
    Summary Hoya Corp (Hoya) is a global med-tech company that manufactures and sells precision devices and instruments built on its advanced optics technologies. Principal products include eyeglass and contact lenses, medical endoscopes, laparoscopic surgical instruments, intraocular lenses, orthopedic …
  • Tokyo Electric Power Company Holdings Incorporated:発電所・企業SWOT分析
    Tokyo Electric Power Company Holdings Incorporated – Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysi …
  • Hankyu Hanshin Holdings, Inc.:企業の戦略・SWOT・財務情報
    Hankyu Hanshin Holdings, Inc. - Strategy, SWOT and Corporate Finance Report Summary Hankyu Hanshin Holdings, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • Banesco Banco Universal C.A.:企業の戦略・SWOT・財務情報
    Banesco Banco Universal C.A. - Strategy, SWOT and Corporate Finance Report Summary Banesco Banco Universal C.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Petroliam Nasional Bhd:石油・ガス:M&Aディール及び事業提携情報
    Summary Petroliam Nasional Bhd (Petronas) is an integrated oil and gas company that explores, develops and produces of oil and natural gas in Malaysia and overseas. It also carries out downstream operations such as processing and liquefaction of natural gas; refining and marketing of petroleum produ …
  • Banque Cantonale Vaudoise (Private Banking):企業の戦略・SWOT・財務情報
    Banque Cantonale Vaudoise (Private Banking) - Strategy, SWOT and Corporate Finance Report Summary Banque Cantonale Vaudoise (Private Banking) - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation …
  • United Engineers Limited:企業の戦略・SWOT・財務情報
    United Engineers Limited - Strategy, SWOT and Corporate Finance Report Summary United Engineers Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Thomson Reuters Corporation:企業のM&A・事業提携・投資動向
    Thomson Reuters Corporation - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Thomson Reuters Corporation Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acq …
  • Autoliv, Inc.:企業の戦略・SWOT・財務情報
    Autoliv, Inc. - Strategy, SWOT and Corporate Finance Report Summary Autoliv, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • First Hotel Company Ltd.:企業の戦略・SWOT・財務情報
    First Hotel Company Ltd. - Strategy, SWOT and Corporate Finance Report Summary First Hotel Company Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Bank of Baroda:企業の戦略・SWOT・財務情報
    Bank of Baroda - Strategy, SWOT and Corporate Finance Report Summary Bank of Baroda - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • Tanita Corp:企業の戦略的SWOT分析
    Tanita Corp - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • Tervita Corp:企業の戦略・SWOT・財務情報
    Tervita Corp - Strategy, SWOT and Corporate Finance Report Summary Tervita Corp - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Semma Therapeutics Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Semma Therapeutics Inc (Semma Therapeutics) is a biotechnology company that develops cell replacement therapy for the treatment of diabetes. The company develops therapies using stem cells of the individuals with Type 1 diabetes to produce their own insulin that will regulate the blood sugar …
  • Greenleaf Power LLC:電力:M&Aディール及び事業提携情報
    Summary Greenleaf Power LLC (Greenleaf Power) is a provider of renewable energy services in North America. The company acquires and operates base-load biomass plants to generate electricity. It collects residual biomass material from agricultural, construction, demolition, landfill, and timber indus …
  • Invenergy LLC:企業の発電所・SWOT分析2018
    Invenergy LLC - Power Plants and SWOT Analysis, 2018 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key employees (exec …
  • Calypso Biotech SA-製薬・医療分野:企業M&A・提携分析
    Summary Calypso Biotech SA (Calypso) is a biopharmaceutical company that develops antibody therapies. The company’s pipeline products include CALY-0001 and CALY-0002. Its CALY-0001 therapeutic antibody is used in the treatment of Crohn’s disease; and CALY-0002 a humanized monoclonal antibody used in …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆